ServiziMenu principaleHome
Home > About us > Organizational structure > Executive Committee > Elzbieta Senkus - Konefka

Elzbieta Senkus - Konefka

Elzbieta Senkus-Konefka
Medical University of Gdansk
Debinki, 7
80-211 Gdansk, POLAND


Elzbieta Senkus-Konefka is an Associate Professor at the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland. She graduated from the Medical University of Gdańsk and finished training in Radiation Oncology in 1998 and in Medical Oncology in 2004.
In 1995 she obtained a PhD on brachytherapy of cervical cancer.
Her main scientific interests in breast cancer include molecular basis of this disease in high-risk patients and special phenotypes of breast cancer. She is a Faculty Member for Breast Cancer of ESMO and ESO and was involved (2015-2020) in developing international guidelines for early and metastatic breast cancer as the Section Editor of ESMO Guidelines Committee.
Since 2009 she is a Specialty Editor for “The Breast” and has been actively involved in undergraduate and postgraduate teaching, including courses organized by ESTRO, ESMO and ESO. She also served on Scientific Committees and/or Consensus Expert Panels of ESMO,
European Breast Cancer Conference (EBCC), Advanced Breast Cancer (ABC) and Breast Cancer in Young Women (BCY) conferences. Since 2013 she is a member of the Steering Committee and in years 2017-19 served as a Secretary of the EORTC Breast Cancer Group.
She has been involved as a leader or partner in research projects supported by national (Medical Research Agency, National Science Center) and international (Horizon 2020, COST) grants. 
She has contributed to over 150 peer-reviewed publications, 21 book chapters and was a co-editor of 2 textbooks. Cumulated impact factor of publications: 1312; 13411 citations, h-score 47 (Scopus database, viewed Oct. 11, 2023).
She has two sons of 28 and 26. Her hobbies include traveling, skiing and designing jewellery.

Most relevant papers

E. Senkus-Konefka
D. Pasquier, L. Bidaut, D.E. Oprea-Lager, N.M. deSouza, D. Krug, L. Collette, W. Kunz, Y. Belkacemi, M.G. Bau, C. Caramella, L.-F. De Geus-Oei, A. De Caluwé, C. Deroose, O. Gheysens, K. Herrmann, I. Kindts, M. Kontos, S. Küemmel, B. Linderholm, E. Lopci, I. Meattini, A. Smeets, O. Kaidar-Person, P. Poortmans, P. Tsoutsou, N. Hajjaji, N. Russell, E. Senkus, J.-N. Talbot, L. Umutlu, V. Vandecaveye, J. Verhoeff, W. Menke - van der Houven van Oordt, H.D. Zacho, F. Cardoso, L. Fournier, F. Van Duijnhoven, F.E. Lecouvet
Designing clinical trials based on modern imaging and metastatic-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups
Lancet Oncol 2023; 24: e331–43

E. Senkus-Konefka
E. Senkus, S. Delaloge, S.M. Domchek, P. Conte, S.-A. Im, B. Xu, A. Armstrong, N. Masuda, A. Fielding, M. Robson, N. Tung.
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial
Int J Cancer. 2023; 153: 803–814. doi: 10.1002/ijc.34525.

E. Senkus-Konefka
K. Van Baelen, T. Geukens, M. Maetens, V. Tjan-Heijnen, W.W. Yang, R.E. Steele, S.J. Pettitt, C.J. Lord, S. Linn, F.-C. Bidard, C. Van Ongeval, M. De Schepper, E. Isnaldi, I. Nevelsteen, A. Smeets, K. Punie, L. Voorwerk, H. Wildiers, G. Floris, P. Neven, E. Senkus, E. Sawyer, M. Kok, C. Desmedt.
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
Ann Oncol 2022; 33: 769-785 (doi.org/10.1016/j.annonc.2022.05.006).

E. Senkus-Konefka
Meattini; C. Becherini; L. Boersma; O. Kaidar-Person; G. Nader Marta; A. Montero; B.V. Offersen; M.C. Aznar; C. Belka; A.M. Brunt; S. Dicuonzo; P. Franco; M. Krause; M. MacKenzie; T. Marinko; L. Marrazzo; I. Ratosa; E. Senkus-Konefka; A. Scholten; H. Stobart; P. Poortmans; C.E. Coles.
European Society for Radiotherapy and Oncology (ESTRO) Advisory Committee in Radiation Oncology Practice (ACROP) consensus recommendations on patient selection and dose/fractionation for external beam radiation therapy in early breast cancer.
Lancet Oncol 2022; 23: e21–31

E. Senkus-Konefka
S. Paluch-Shimon, F. Cardoso, A.H. Partridge, O. Abulkhair, H.A. Azim Jr, G. Bianchi-Micheli, M.-J. Cardoso, G. Curigliano, K.A Gelmon, O. Gentilini, N. Harbeck, B. Kaufman, S.B. Kim, Q. Liu, J. Merschdorf, P. Poortmans, G. Pruneri, E. Senkus, B. Sirohi, T. Spanic, V. Sulosaari, F. Peccatori, O. Pagani.
ESO-ESMO 5th International Consensus Guidelines for Breast Cancer in Young Women (BCY5).
Ann Oncol 2022; 33: 1097-1118 (doi: 10.1016/j.annonc.2022.07.007)

E. Senkus-Konefka
N. Harbeck, P. Rastogi, M. Martin, S. M. Tolaney, Z. M. Shao, P. A. Fasching, C. S. Huang, G. G. Jaliffe, A. Tryakin, M. P. Goetz, H. S. Rugo, E. Senkus, L. Testa, M. Andersson, K. Tamura, L. Del Mastro, G. G. Steger, H. Kreipe, R. Hegg, J. Sohn, V. Guarneri, J. Cortés, E. Hamilton, V. Andre, R. Wei, S. Barriga, S. Sherwood, T. Forrester, M. Munoz, A. Shahir, B. San Antonio, S. C. Nabinger, M. Toi, S. R .D. Johnston, J. O’Shaughnessy.
Adjuvant Abemaciclib Combined with Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis from the monarchE study.
Ann Oncol 2021; 32: 1571-1581. (DOI: 0.1016/j.annonc.2021.09.015)

E. Senkus-Konefka
Tutt, J. Garber, B. Kaufman, G. Viale, D. Fumagalli, P. Rastogi, R. Gelber, E. de Azambuja, A. Fielding, J. Balmaña, S. Domchek, K.A Gelmon, S.J Hollingsworth, L. Korde, B. Linderholm, H. Bandos, E. Senkus, J.M. Suga, Z. Shao, A.W. Pippas, Z. Nowecki, T. Huzarski, P.A. Ganz, P.C Lucas, N. Baker, S. Loibl, R. McConnell, M. Piccart, R. Schmutzler, G. Steger, J.P Costantino, A. Arahmani, N. Wolmark, E. McFadden, V. Karantza, S. Lakhani, G. Yothers, C. Campbell, C.E Geyer.
Adjuvant olaparib after chemotherapy in patients with germline BRCA1/2 mutation associated HER2-negative early breast cancer.
N Engl J Med. 2021; 384:2394-2405 (DOI: 10.1056/NEJMoa2105215)

E. Senkus-Konefka
E. Senkus, M.J. Cardoso, O. Kaidar-Person, A. Lacko, I. Meattini, P. Poortmans:
De-escalation of axillary irradiation for early breast cancer – Has the time come?
Cancer Treat Rev 2021; 101: 102297 (DOI: 10.1016/j.ctrv.2021.102297)

E. Senkus-Konefka
F. Cardoso, E. Senkus-Konefka, L. Fallowfield, A. Costa, M. Castiglione on behalf of the ESMO Guidelines Working Group
Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann Oncol 2010, 21 (Suppl. 5): v15–v19.

E. Senkus-Konefka
O. Pagani, E. Senkus-Konefka, W. Wood, M. Colleoni, T. Cufer, S. Kyriakides, A. Costa, E. P. Winer, F. Cardoso
International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: Can metastatic breast cancer be cured?
JNCI 2010;102:456–463

E. Senkus-Konefka
F. Cardoso, P.L. Bedard, E. Winer, O. Pagani, E. Senkus-Konefka, L. Fallowfield, S. Kyriakides, A. Costa, T Cufer, K.S. Albain on behalf of the ESO-MBC Task Force
International guidelines for management of metastatic breast cancer: Combination versus sequential single agent chemotherapy.
JNCI 2009; 101: 1174-81.